For research use only. Not for therapeutic Use.
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al[1][2][3][4][5].
Aviptadil (500 μg/kg; Intravenous injection; Every other day; Three weeks) completely prevented and significantly reversed Monocrotaline (MCT) (HY-N0750) -induced Pulmonary Arterial Hypertension in Sprague Dawley rat models (PAH)). Aviptadil is synergistic with Bosentan (HY-A0013)[3].
Aviptadil (150 μg/kg/d; Intraperitoneal pump; 2.5 μl/h; 4 weeks) can eliminate bronchial hyperreactivity (BHR) in Sprague-Dawley rats, with a characteristic of bronchiectasis[3].
Aviptadil (0.1, 3 μg/kg; Intravenous injection (i.v.)) can improve reperfusion injury in living rat lung transplantation models[5].
| Catalog Number | I003308 |
| CAS Number | 40077-57-4 |
| Molecular Formula | C147H238N44O42S |
| Purity | ≥95% |
| Reference | [1]. Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure (COVID-AIV) [2]. Jian Hu, et al. Novel Targets of Drug Treatment for Pulmonary Hypertension. Am J Cardiovasc Drugs [3]. Hamidi SA, et al. VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension. Respir Res. 2011;12(1):141. Published 2011 Oct 26. [4]. Hamidi SA, et al. VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension. Respir Res. 2011;12(1):141. Published 2011 Oct 26. [5]. Nagahiro I, et al. Vasoactive intestinal peptide ameliorates reperfusion injury in rat lung transplantation. J Heart Lung Transplant. 1998;17(6):617-621. |
